We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

33 hedge funds and large institutions have $5.86M invested in Rein Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.21% less ownership

Funds ownership: 1.77% → 1.56% (-0.21%)

11% less funds holding

Funds holding: 37 → 33 (-4)

30% less capital invested

Capital invested by funds: $8.34M → $5.86M (-$2.49M)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
33
Holders Change
-4
Holders Change %
-10.81%
% of All Funds
0.57%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
8
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$16.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$15.9K
3
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$13.4K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$10.6K
5
Osaic Holdings
Osaic Holdings
Arizona
+$5.12K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$752K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$103K
3
BFM
Boothbay Fund Management
New York
-$72K
4
KL
KCK Ltd
Bermuda
-$42.2K
5
TCA
Taconic Capital Advisors
New York
-$35K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Alerce Investment Management
Illinois
$3.43M – – –
BI
2
BVF Inc
California
$1.09M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$539K -$103K -24,406 -16%
William Blair & Company
4
William Blair & Company
Illinois
$254K +$16.5K +3,911 +7%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$183K +$2.82K +668 +2%
KL
6
KCK Ltd
Bermuda
$101K -$42.2K -10,000 -31%
Renaissance Technologies
7
Renaissance Technologies
New York
$39K +$15.9K +3,775 +66%
Envestnet Asset Management
8
Envestnet Asset Management
Illinois
$38K +$13.4K +3,182 +53%
PAM
9
PVG Asset Management
Colorado
$24.3K +$24.8K +5,880 New
Northern Trust
10
Northern Trust
Illinois
$24K – – –
GPFA
11
Game Plan Financial Advisors
Ohio
$21K -$634 -150 -3%
State Street
12
State Street
Massachusetts
$21K – – –
CG
13
Colony Group
Massachusetts
$19K – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$14K +$5.12K +1,213 +57%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$10K +$10.6K +2,521 New
JWA
16
JFS Wealth Advisors
Pennsylvania
$7K – – –
KAS
17
Kestra Advisory Services
Texas
$6K – – –
US Bancorp
18
US Bancorp
Minnesota
$5K – – –
Morgan Stanley
19
Morgan Stanley
New York
$5K +$4 +1 +0.1%
Cetera Investment Advisers
20
Cetera Investment Advisers
Illinois
$5K +$1.85K +437 +50%
Mercer Global Advisors
21
Mercer Global Advisors
Colorado
$4K – – –
LPL Financial
22
LPL Financial
California
$4K +$2.11K +500 +100%
LSAG
23
Lake Street Advisors Group
New Hampshire
$3K -$422 -100 -11%
KPW
24
Kore Private Wealth
New York
$2K – – –
RWP
25
Ridgecrest Wealth Partners
California
$2K – – –
1
2

RNTX Hedge Fund Activity: Q3 2022 in Review

33 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2022, worth a combined $5.86M — down 30% from $8.34M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of RNTX and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.

The largest buyer was William Blair & Company, adding an estimated $16.5K. The largest seller was Ikarian Capital, exiting entirely with an estimated $752K sold.

  • 33 institutional investors held Rein Therapeutics (RNTX) as of Q3 2022, down from 37 in Q2 2022.
  • Funds reported $5.86M of Rein Therapeutics stock for Q3 2022, down 30% quarter-over-quarter.
  • 4 funds opened new Rein Therapeutics positions in Q3 2022 and 7 closed out, a net change of -3 holders.
  • The largest Rein Therapeutics buyer in Q3 2022 was William Blair & Company, an estimated $16.5K added.
  • The largest Rein Therapeutics seller in Q3 2022 was Ikarian Capital, an estimated $752K sold.

Based on aggregated 13F filings for Q3 2022.